Have you looked into how Haemonetics (HAE) performed internationally during the quarter ending June 2026? Considering the widespread global presence of this provider blood management systems for health care providers and blood collectors, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.
The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.
Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.
While analyzing HAE's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The recent quarter saw the company's total revenue reaching $339.38 million, marking an improvement of 5.6% from the prior-year quarter. Next, we'll examine the breakdown of HAE's revenue from abroad to comprehend the significance of its international presence.
Trends in HAE's Revenue from International Markets
Of the total revenue, $45.53 million came from Europe during the last fiscal quarter, accounting for 13.4%. This represented a surprise of +1.54% as analysts had expected the region to contribute $44.84 million to the total revenue. In comparison, the region contributed $52.9 million, or 15.3%, and $40.88 million, or 12.7%, to total revenue in the previous and year-ago quarters, respectively.
During the quarter, Other International contributed $2.99 million in revenue, making up 0.9% of the total revenue. When compared to the consensus estimate of $2.81 million, this meant a surprise of +6.26%. Looking back, Other International contributed $3.11 million, or 0.9%, in the previous quarter, and $2.81 million, or 0.9%, in the same quarter of the previous year.
Japan accounted for 3.8% of the company's total revenue during the quarter, translating to $12.86 million. Revenues from this region represented a surprise of -9.58%, with Wall Street analysts collectively expecting $14.22 million. When compared to the preceding quarter and the same quarter in the previous year, Japan contributed $18.4 million (5.3%) and $13.65 million (4.3%) to the total revenue, respectively.
Revenue Forecasts for the International Markets
It is projected by analysts on Wall Street that Haemonetics will post revenues of $344.82 million for the ongoing fiscal quarter, an increase of 5.4% from the year-ago quarter. The expected contributions from Europe, Other International and Japan to this revenue are 12.8%, 0.8%, and 5%, translating into $44.07 million, $2.65 million, and $17.17 million, respectively.For the full year, the company is expected to generate $1.41 billion in total revenue, up 5.8% from the previous year. Revenues from Europe, Other International and Japan are expected to constitute 12.9% ($182.19 million), 0.9% ($12.51 million) and 4.8% ($67.42 million) of the total, respectively.
Wrapping Up
The dependency of Haemonetics on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.
In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.
At Zacks, a company's changing earnings outlook is given considerable attention due to its proven, strong influence on a stock's price performance in the near term. The connection here is straightforward and positive: when earnings estimates are revised upward, the stock price generally follows suit, increasing as well.
The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.
At the moment, Haemonetics has a Zacks Rank #3 (Hold), signifying that its performance may align with the overall market trend in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
A Look at Haemonetics' Recent Stock Price Performance
The stock has increased by 12.6% over the past month compared to the 2.5% increase of the Zacks S&P 500 composite. Meanwhile, the Zacks Medical sector, which includes Haemonetics,has increased 3.3% during this time frame. Over the past three months, the company's shares have experienced a gain of 51.2% relative to the S&P 500's 5.1% increase. Throughout this period, the sector overall has witnessed a 12.9% increase.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Haemonetics Corporation (HAE): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).